Condition
CIPN
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Unknown2
Recruiting1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT04986891RecruitingPrimary
Chemotherapy Induced Peripheral Neurotoxicity (CIPN): Why Should we Care
NCT06711978Not ApplicableNot Yet RecruitingPrimary
Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors
NCT05382520Not ApplicableUnknownPrimary
Sensory Rehabilitation in Chemotherapy Induced Peripheral Neuropathy (CIPN)
NCT05434403Not ApplicableUnknownPrimary
Transauricular Vagus Nerve Stimulation in the Treatment of Chemotherapy-induced Peripheral Neuropathy
Showing all 4 trials